PRPH - ProPhase Labs, Inc.

NasdaqCM - NasdaqCM Delayed price. Currency in USD
2.36
-0.01 (-0.42%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous close2.37
Open2.36
Bid2.35 x 1000
Ask2.40 x 5000
Day's range2.35 - 2.38
52-week range1.78 - 2.53
Volume23,773
Avg. volume9,235
Market cap29.331M
Beta0.80
PE ratio (TTM)0.98
EPS (TTM)2.40
Earnings date27 Mar 2017 - 31 Mar 2017
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est15.55
Trade prices are not sourced from all markets
  • Globe Newswire2 months ago

    ProPhase Labs, Inc. Announces Final Results of Its Tender Offer

    ProPhase Labs, Inc. (NASDAQ:PRPH) (www.ProPhaseLabs.com), a diversified natural health medical science company (“ProPhase”), announced today the final results of its tender offer to purchase up to 1,700,000 shares of its common stock at a price of $2.30 per share, which expired at midnight, New York City time, on December 18, 2017. ProPhase has accepted for purchase 1,948,569 shares of its Common Stock, including all “odd lots” validly tendered, at a purchase price of $2.30 per share, for an aggregate purchase price of approximately $4.5 million. Based on the final tabulation by American Stock Transfer & Trust Company, the Depositary for the tender offer, 2,072,280 shares of ProPhase Common Stock were properly tendered and not withdrawn.

  • We're sorry this is all we were able to find about this topic.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes